Coya Therapeutics: Developing Treatments For Serious Neurodegenerative And Autoimmune Diseases

Summary

• Coya Therapeutics’ pipeline candidates focus on improving the quantity and functionality of regulatory T cells to alleviate the inflammatory processes associated with the progression of neurodegenerative and autoimmune diseases.
• Regulatory T cells, or Tregs, constitute a significant class of T-cells that utilize their anti-inflammatory properties to maintain immune balance or homeostasis.
• The release of the data in patients with AD follows the recent results from the COYA 302 Proof-of-concept study in patients with ALS that showed amelioration of disease progression.
• The expected release of results from the COYA 301 Proof-of-concept study in patients with AD in May 2023 serves as a substantial near-term catalyst with the potential to elevate the company's market value.
• Coya’s pipeline candidates have undergone the initial human trials depicting the efficacy and safety of the company’s Treg-modulating therapies in slowing the progression of ALS and Alzheimer’s disease (AD).

Artur Plawgo

Introduction and Investment Thesis

My interest in Coya Therapeutics (NASDAQ:COYA) stems from its innovative and straightforward approach to modulating the function of regulatory T cells (Tregs) to address the underlying inflammatory processes in complex neurodegenerative and autoimmune conditions with significant unmet

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours.

Business relationship disclosure:Coya Therapeutics is a client of Quantum Media Group, LLC